Fly News Breaks for May 28, 2019
May 28, 2019 | 07:41 EDT
Cantor Fitzgerald analyst Charles Duncan raised his price target for Axsome Therapeutics to $35 from $25 and reiterates an Overweight rating on the shares. The analyst says his discussions with key opinion leaders at the American Psychiatric Association conference enhanced his conviction on the company's path forward in depression. He sees an "asymmetric" reward/risk scenario, despite the move in the stock already in 2019, heading into expected top line Phase 3 data from the Stride-1 trial.
News For AXSM From the Last 2 Days
There are no results for your query AXSM